Immediate hypersensitivity reactions following monovalent 2009 pandemic influenza A (H1N1) vaccines: reports to VAERS
- PMID: 24120547
- DOI: 10.1016/j.vaccine.2013.09.066
Immediate hypersensitivity reactions following monovalent 2009 pandemic influenza A (H1N1) vaccines: reports to VAERS
Abstract
Background: Hypersensitivity disorders following vaccinations are a cause for concern.
Objective: To determine the type and rate by age, gender, and vaccine received for reported hypersensitivity reactions following monovalent 2009 pandemic influenza A (H1N1) vaccines.
Design: A systematic review of reports to the Vaccine Adverse Event Reporting System (VAERS) following monovalent 2009 pandemic influenza A (H1N1) vaccines.
Setting/patients: US Civilian reports following vaccine received from October 1, 2009 through May 31, 2010.
Measurements: Age, gender, vaccines received, diagnoses, clinical signs, and treatment were reviewed by nurses and physicians with expertise in vaccine adverse events. A panel of experts, including seven allergists reviewed complex illnesses and those with conflicting evidence for classification of the event.
Results: Of 1984 reports, 1286 were consistent with immediate hypersensitivity disorders and 698 were attributed to anxiety reactions, syncope, or other illnesses. The female-to-male ratio was ≥4:1 for persons 20-to-59 years of age, but approximately equal for children under 10. One hundred eleven reports met Brighton Collaboration criteria for anaphylaxis; only one-half received epinephrine for initial therapy. The overall rate of reported hypersensitivity reactions was 10.7 per million vaccine doses distributed, with a 2-fold higher rate for live vaccine.
Limitations: Underreporting, especially of mild events, would result in an underestimate of the true rate of immediate hypersensitivity reactions. Selective reporting of events in adult females could have resulted in higher rates than reported for males.
Conclusions: Adult females may be at higher risk of hypersensitivity reactions after influenza vaccination than men. Although the risk of hypersensitivity reactions following 2009 pandemic influenza A (H1N1) vaccines was low, all clinics administering vaccines should be familiar with treatment guidelines for these adverse events, including the use of intramuscular epinephrine early in the course of serious hypersensitivity reactions.
Keywords: Allergic reactions; Anaphylaxis; H1N1 influenza vaccine; Hypersensitivity; Immunization; Influenza vaccine; Urticaria.
Copyright © 2013 Elsevier Ltd. All rights reserved.
Similar articles
-
Events supposedly attributable to vaccination or immunization during pandemic influenza A (H1N1) vaccination campaigns in Latin America and the Caribbean.Vaccine. 2015 Jan 1;33(1):187-92. doi: 10.1016/j.vaccine.2014.10.070. Epub 2014 Nov 6. Vaccine. 2015. PMID: 25444798
-
Safety of pandemic H1N1 vaccines in children and adolescents.Vaccine. 2011 Oct 6;29(43):7559-71. doi: 10.1016/j.vaccine.2011.08.016. Epub 2011 Aug 5. Vaccine. 2011. PMID: 21821086 Review.
-
Immunization-safety monitoring systems for the 2009 H1N1 monovalent influenza vaccination program.Pediatrics. 2011 May;127 Suppl 1:S78-86. doi: 10.1542/peds.2010-1722L. Epub 2011 Apr 18. Pediatrics. 2011. PMID: 21502251 Review.
-
Adverse events following influenza A (H1N1) 2009 monovalent vaccines reported to the Vaccine Adverse Event Reporting System, United States, October 1, 2009-January 31, 2010.Vaccine. 2010 Oct 21;28(45):7248-55. doi: 10.1016/j.vaccine.2010.09.021. Epub 2010 Sep 16. Vaccine. 2010. PMID: 20850534
-
Safety of influenza A (H1N1) 2009 monovalent vaccines - United States, October 1-November 24, 2009.MMWR Morb Mortal Wkly Rep. 2009 Dec 11;58(48):1351-6. MMWR Morb Mortal Wkly Rep. 2009. PMID: 20010511
Cited by
-
The Importance of Gender-Sensitive Health Care in the Context of Pain, Emergency and Vaccination: A Narrative Review.Int J Environ Res Public Health. 2023 Dec 21;21(1):13. doi: 10.3390/ijerph21010013. Int J Environ Res Public Health. 2023. PMID: 38276801 Free PMC article. Review.
-
Association of the Magnitude of Anti-SARS-CoV-2 Vaccine Side Effects with Sex, Allergy History, Chronic Diseases, Medication Intake, and SARS-CoV-2 Infection.Vaccines (Basel). 2024 Jan 20;12(1):104. doi: 10.3390/vaccines12010104. Vaccines (Basel). 2024. PMID: 38276676 Free PMC article.
-
The Safety and Effectiveness of mRNA Vaccines Against SARS-CoV-2.Cureus. 2023 Sep 20;15(9):e45602. doi: 10.7759/cureus.45602. eCollection 2023 Sep. Cureus. 2023. PMID: 37868494 Free PMC article. Review.
-
Allergic reactions to the Ad26.COV2.S vaccine in South Africa.J Allergy Clin Immunol Glob. 2021 Dec 9;1(1):2-8. doi: 10.1016/j.jacig.2021.12.002. eCollection 2022 Feb. J Allergy Clin Immunol Glob. 2021. PMID: 37780073 Free PMC article.
-
Self-reported side effects following COVID-19 vaccination in athletes: A retrospective study.Hum Vaccin Immunother. 2023 Aug 1;19(2):2234788. doi: 10.1080/21645515.2023.2234788. Hum Vaccin Immunother. 2023. PMID: 37470390 Free PMC article.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Miscellaneous